Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2025 | $21.00 | Buy | Chardan Capital Markets |
| 4/8/2025 | Outperform | William Blair | |
| 3/18/2025 | $17.00 | Outperform | RBC Capital Mkts |
| 3/11/2025 | $15.00 | Buy | Needham |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 6/20/2024 | $7.00 → $11.00 | Hold → Buy | TD Cowen |
| 5/31/2024 | $15.00 | Overweight | Piper Sandler |
| 2/9/2024 | $15.00 | Buy | BofA Securities |
Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00
William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform
RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 - 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 TrialSession Date/Time: Thursday, October 9, 2025, 4:30 – 6:30 PM ETPresenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix Eyecelerator @ AAO 2025
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular", the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about October 1, 2025, subject to the satisfaction of customary closing conditions. BofA S
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient selection strategy, trial design, and potential SOL-1 success could drive confidence in SOL-R outcomes; topline data on track for 1H 2027 Will showcase planned HELIOS-2 and HELIOS-3 registrational trials to evaluate AXPAXLI in non-proliferative diabetic retinopathy (NPDR) using novel primary endpoint, aligned with FDA in HELIOS-2 Special Protocol Assessment (SPA) agreement To outline SOL-X open label extension program and AXPAXLI's potential to improve lon
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
424B5 - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance of $391.1 million as of June 30, 2025, with expected runway into 2028, well beyond anticipated topline data for SOL-1 and SOL-R BEDFORD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Thera
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877-407-9039 Participant Dial-In (International): 1-201-689-8470 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix webs
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)